An observational study in Smoking, Smoking Behaviors and Smoking Cessation, sponsored by Virginia Commonwealth University. Completed at 2 sites in United States. Open to male participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Virginia Commonwealth University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 899 studies in Smoking with a site in United States — 90 open to participants now, 110 under way, 4 of them phase 3. Smoking · United States.
Among the 899 studies in Smoking with a site in United States, this one is the 66th largest by enrollment of the 108 observational ones that give a count, is one of 35 that started in 2024, is one of 110 observational ones, and was the 770th registered.
1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.
Browse Smoking studies →90 of the 899 studies in Smoking with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+
Georgia State University · Sites in United States
Ages 21+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 75 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
899 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 112 · Phase 3 64 · Phase 4 67
First in 1993; this study’s year is marked. 35 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is below the median of 150 across 305 observational studies indexed under Smoking.
Median enrollment 109 across the 785 interventional studies, 131 across the 108 observational. Of the 742 that completed or were terminated, 293 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 899 have an industry lead sponsor. The 10 most frequent:
Virginia Commonwealth University is the lead sponsor of 648 studies on the registry; 79 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 64 (71%) have results posted.
Virginia Commonwealth University has 7 studies filed under Smoking — fewer than ten, so there is no comparison to draw.
57 of the studies in Smoking with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07119489Wake Forest University Health SciencesA Novel Dialectical Behavior Therapy Brief Group Intervention for Cigarette Smoking by Patients With Cancer: An Open Clinical Trial | 2026-11 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT04968249University of MichiganMichigan Early Disease Progression Cohort | 2026-12 |
| NCT07710820RAI Services CompanyA Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers | 2026-12 |
| NCT06837220University of ChicagoImplementation of Tobacco Cessation Programming at Community Behavioral Health Sites | 2026-12 |
Add all 57 to your calendar (.ics) → With an account.
Among the 899 studies in Smoking with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine racial differences in smoking behaviors and stress responses between African American and white male smokers.
Cigarette smoking is a leading cause of morbidity and mortality from lung cancer among adults in the US. Stress relief and smoking cessation is the best preventive strategy for reducing lung cancer risk and addressing racial disparities in outcomes. Despite this, racial differences are found among those that make quit attempts. Stress has been found to be related to smoking initiation, maintenance, and relapse. Yet, differences in stress responses have not been examined between African American and white smokers. Therefore, this study will examine racial differences in stress responses and smoking behaviors between African American and white male smokers
African American and white male daily smokers who are between the ages of 18-75 and who smoke at least 5 to 10 cigarettes per day.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
African American male smokers
White male smokers
Examining Racial Differences in Cortisol During TSST Which Activates Acute Stress Responses
Examine racial differences in acute stress responses using a validated psychological stress challenge called the Trier Social Stress Test (TSST). This aim will examine racial disparities in cortisol responses to an acute stressor among AA/Black and white male smokers in a laboratory setting. Changes in cortisol levels will be the primary outcome variable and will be measured multiple times during the course of the TSST. To examine the effects of race on acute stress responses to the TSST laboratory stressors the response area under the curve (rAUC) for cortisol will be calculated using trapezoidal approximation with the samples obtained at time zero (T0) to the last measurement (T24m).
Time frame: 90-minute laboratory stress test, scheduled after completion of baseline health survey
Examining Changes in Daily Cortisol Patterns According to Race for Those Who Completed TSST.
Examine racial differences in daily diurnal cortisol slopes to evaluate hypothalamic-pituitary-adrenal-axis dysregulation and acute stress. A higher score means a flatter slope, and reflects higher chronic stress. No scale for slope.
Time frame: 4- week and 8-week at-home post-TSST home post TSST daily saliva (cortisol) data collection
Examine the Relationship Between Perceived Stress and Smoking Behavior Across Groups
Assessed perceived stress using the 4-item Perceived Stress Scale (PSS-4), a validated self-report measure of how stressful an individual's life situations are perceived to be. Participants rate each item on a 5-point scale from 0 (never) to 4 (very often). Positively worded items are reverse-scored, and the four items are summed to produce a total score ranging from 0 to 16. Higher scores indicate greater perceived stress. Stress is compared for those who reported at least 1 quit attempt within the past 12 months and for those who did not.
Time frame: Baseline health survey pre-TSST
| Milestone | Baseline Health Survey and Trier Social Stress Test (TSST)- African American Men | Baseline Health Survey and Trier Social Stress Test (TSST)- White Men |
|---|---|---|
| Started | 37 | 55 |
| Completed | 14 | 18 |
| Not completed | 23 | 37 |
| Withdrew: Lost to follow-up | 23 | 37 |
Examine racial differences in acute stress responses using a validated psychological stress challenge called the Trier Social Stress Test (TSST). This aim will examine racial disparities in cortisol responses to an acute stressor among AA/Black and white male smokers in a laboratory setting. Changes in cortisol levels will be the primary outcome variable and will be measured multiple times during the course of the TSST. To examine the effects of race on acute stress responses to the TSST laboratory stressors the response area under the curve (rAUC) for cortisol will be calculated using trapezoidal approximation with the samples obtained at time zero (T0) to the last measurement (T24m).
| mcg*min/dL | Baseline Health Survey and Trier Social Stress Test (TSST)- African American Men | Baseline Health Survey and Trier Social Stress Test (TSST)- White Men |
|---|---|---|
| Examining Racial Differences in Cortisol During TSST Which Activates Acute Stress Responses | 9.77 (2.42 to 21.43) | 7.02 (2.73 to 11.18) |
Examine racial differences in daily diurnal cortisol slopes to evaluate hypothalamic-pituitary-adrenal-axis dysregulation and acute stress. A higher score means a flatter slope, and reflects higher chronic stress. No scale for slope.
| Daily Diurnal Slope (mcg/dl/hr) | Baseline Health Survey and Trier Social Stress Test (TSST)-African American Men | Baseline Health Survey and Trier Social Stress Test (TSST)-White Men |
|---|---|---|
| 4 Week Sample | -0.01688 (-0.042 to 0.0114) | -0.02019 (-0.0639 to 0.0164) |
| 8 Week Sample | -0.02051 (-0.0438 to 0.0058) | -0.02038 (-0.0495 to 0.0014) |
Assessed perceived stress using the 4-item Perceived Stress Scale (PSS-4), a validated self-report measure of how stressful an individual's life situations are perceived to be. Participants rate each item on a 5-point scale from 0 (never) to 4 (very often). Positively worded items are reverse-scored, and the four items are summed to produce a total score ranging from 0 to 16. Higher scores indicate greater perceived stress. Stress is compared for those who reported at least 1 quit attempt within the past 12 months and for those who did not.
| Points on perceived stress scale | Baseline Health Survey and Trier Social Stress Test (TSST)- African American Men | Baseline Health Survey and Trier Social Stress Test (TSST)- White Men |
|---|---|---|
| PSS-4 score x Quit Attempt | 6.53 ± 2.70 | 7.50 ± 2.73 |
| PSS-4 score x No Quit Attempt | 6.53 ± 3.88 | 6.00 ± 3.25 |
Collected over From survey initiation to the end of cortisol sample collection; adverse events monitored through study completion, average of 3 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baseline Health Survey and Trier Social Stress Test (TSST)-African American Men | 0/37 (0%) | 0/37 (0%) | 0/37 (0%) |
| Baseline Health Survey and Trier Social Stress Test (TSST)-White Men | 0/55 (0%) | 0/55 (0%) | 0/55 (0%) |
| Age, Continuous(years) | Baseline Health Survey and Trier Social Stress Test (TSST)- African American Men | Baseline Health Survey and Trier Social Stress Test (TSST)- White Men | Total |
|---|---|---|---|
| Mean | 50.69 ± 13.14 | 45.38 ± 13.84 | 47.5 ± 1.482 |
| Sex: Female, Male(Participants) | Baseline Health Survey and Trier Social Stress Test (TSST)- African American Men | Baseline Health Survey and Trier Social Stress Test (TSST)- White Men | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 37 | 55 | 92 |
| Ethnicity (NIH/OMB)(Participants) | Baseline Health Survey and Trier Social Stress Test (TSST)- African American Men | Baseline Health Survey and Trier Social Stress Test (TSST)- White Men | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 13 | 15 |
| Not Hispanic or Latino | 28 | 36 | 64 |
| Unknown or Not Reported | 7 | 6 | 13 |
| Race (NIH/OMB)(Participants) | Baseline Health Survey and Trier Social Stress Test (TSST)- African American Men | Baseline Health Survey and Trier Social Stress Test (TSST)- White Men | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 37 | 0 | 37 |
| White | 0 | 55 | 55 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Baseline Health Survey and Trier Social Stress Test (TSST)- African American Men | Baseline Health Survey and Trier Social Stress Test (TSST)- White Men | Total |
|---|---|---|---|
| United States | 37 | 55 | 92 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2024 to primary completion in Aug 2025, 19 months.
Results were first posted in Nov 2026, 1 year 2 months after primary completion.
Of 83 non-industry observational studies under Smoking, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 114. This study's 19 months is below that.
Counting every sponsor, half of 90 studies reached it within 37 months; a quarter within 14 and three quarters within 103.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Virginia Commonwealth University →